What are the major opportunities in the Primary Biliary Cholangitis Therapeutics market? What are the strategies for the Primary Biliary Cholangitis Therapeutics market?

For detailed insights on the major opportunities and strategies in the Primary Biliary Cholangitis Therapeutics market, Read More

How does the Primary Biliary Cholangitis Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Primary Biliary Cholangitis Therapeutics's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Primary Biliary Cholangitis Therapeutics market growth? SWOT analysis of the Primary Biliary Cholangitis Therapeutics market.

For detailed insights on the key dynamics influencing the Primary Biliary Cholangitis Therapeutics market growth and SWOT analysis of the Primary Biliary Cholangitis Therapeutics industry, Read More

Global Primary Biliary Cholangitis Therapeutics Market Report 2025

Item added to cart!

Published : December 2025

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Primary Biliary Cholangitis Therapeutics Global Market Report 2025

Name: Primary Biliary Cholangitis Therapeutics Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug (Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs), By Mechanism Of Action (MOA) (Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action), By Distribution Channel (Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies), By Use (Human, Veterinary) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Primary Biliary Cholangitis Therapeutics Market Overview

• Primary Biliary Cholangitis Therapeutics market size has reached to $0.89 billion in 2024

• Expected to grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%

• Growth Driver: Increasing Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Rising Alcohol Consumption And Liver Damage

• Market Trend: Breakthrough In PBC Treatment With Selective Ppard Activation

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Primary Biliary Cholangitis Therapeutics Market?

Primary biliary cholangitis (PBC) therapeutics refer to treatments designed to manage and slow the progression of primary biliary cholangitis, a chronic autoimmune liver disease that damages the bile ducts. These work by enhancing bile flow, minimizing inflammation, and slowing liver fibrosis. The main purpose of these therapeutics is to reduce liver inflammation, improve bile flow, prevent liver fibrosis, and delay the onset of liver failure.

The main drug types of primary biliary cholangitis therapeutics are ursodeoxycholic acid, obeticholic acid, and others. Ursodeoxycholic acid is a bile acid used to improve liver function by reducing bile buildup and slowing liver damage, especially in cholestatic liver diseases like primary biliary cholangitis. These work by various mechanisms of action (MOA), such as receptor agonist, receptor modulator, enzyme activator, enzyme inhibitor, and others, and are distributed through several distribution channels, including hospital pharmacies, drug stores and retail pharmacies, and online pharmacies, serving key end users, including human and veterinary purposes.

Primary Biliary Cholangitis Therapeutics Market Size and growth rate 2025 to 2029: Graph

What Is The Primary Biliary Cholangitis Therapeutics Market Size 2025 And Growth Rate?

The primary biliary cholangitis therapeutics market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising awareness of autoimmune liver diseases, increasing clinical evidence supporting growth in liver function testing, increasing investment in hepatology research, and rising prevalence of autoimmune diseases.

What Is The Primary Biliary Cholangitis Therapeutics Market Growth Forecast?

The primary biliary cholangitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing adoption of second-line therapies, a growing pipeline of novel therapeutics, a rise in combination therapies, increasing global access to diagnostics and specialty care, and growth in patient advocacy and education initiatives. Major trends in the forecast period include personalized treatment approaches, expansion of second-line therapies, focus on non-invasive biomarkers, emphasis on symptom management, and integration of real-world evidence (RWE).

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Primary Biliary Cholangitis Therapeutics Market Segmented?

1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs

2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action

3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

4) By Use: Human, Veterinary

Subsegments:

1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid

2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid

3) By Other Drugs: Fibrates, Budesonide, immunosuppressants, Investigational Drugs Or Pipeline Candidates

What Is Driving The Primary Biliary Cholangitis Therapeutics Market? Increasing Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Rising Alcohol Consumption And Liver Damage

The increasing prevalence of liver diseases is expected to propel the growth of the primary biliary cholangitis therapeutics market going forward. Liver diseases refer to a group of conditions that impair the normal functioning of the liver, often leading to inflammation, scarring, or liver failure. The increasing prevalence of liver diseases is due to rise in alcohol consumption as excessive alcohol intake damages liver cells, leading to inflammation and chronic liver conditions. Primary biliary cholangitis therapeutics help manage liver diseases by targeting bile duct inflammation, slowing disease progression, and preserving liver function. They improve patient outcomes by reducing symptoms, enhancing quality of life, and delaying the need for liver transplantation. For instance, in March 2022, according to the Centers for Disease Control and Prevention, a US-based government agency, deaths from chronic liver diseases in Texas rose to 5,079, marking an increase from 4,930 in 2021. Therefore, the increasing prevalence of liver diseases is driving the growth of the primary biliary cholangitis therapeutics industry.

Who Are The Major Players In The Global Primary Biliary Cholangitis Therapeutics Market?

Major companies operating in the primary biliary cholangitis therapeutics market are F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

What Are The Key Trends Of The Global Primary Biliary Cholangitis Therapeutics Market? Breakthrough In PBC Treatment With Selective Ppard Activation

Major companies operating in the primary biliary cholangitis therapeutics market are focusing on developing advanced products and obtaining approvals, such as for peroxisome proliferator-activated receptor agonists, to improve bile acid metabolism and slow disease progression in patients. Peroxisome proliferator-activated receptor (PPAR) agonists are drugs that activate PPAR proteins, which regulate genes involved in metabolism, inflammation, and energy balance. For instance, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in adults who have had an inadequate response to ursodeoxycholic acid (UDCA) or cannot tolerate UDCA. It is an oral, selective PPARd agonist that works by activating the PPARd receptor to regulate genes involved in reducing liver inflammation, improving bile acid metabolism, and slowing disease progression in primary biliary cholangitis (PBC).

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Primary Biliary Cholangitis Therapeutics Market? Gilead Acquires CymaBay To Boost Liver Disease Pipeline

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, acquired CymaBay Therapeutics Inc. for $4.3 billion. With this acquisition, Gilead aims to strengthen its liver disease portfolio by adding CymaBay’s investigational therapy, seladelpar, a promising treatment for primary biliary cholangitis (PBC), a rare and chronic liver disease. CymaBay Therapeutics Inc. is a US-based pharmaceutical company that develops and provides innovative therapies for primary biliary cholangitis.

What Is The Regional Outlook For The Global Primary Biliary Cholangitis Therapeutics Market?

North America was the largest region in the acute care telemedicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Care Telemedicine Market?

The acute care telemedicine market includes revenues earned by entities by providing services like virtual emergency care, remote intensive care unit monitoring, tele-stroke evaluations, virtual hospitalist support, and real-time specialist consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Primary Biliary Cholangitis Therapeutics Industry?

The primary biliary cholangitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including the primary biliary cholangitis therapeutics industry global market size, regional shares, competitors with the market share, detailed market segments, market trends, opportunities, and any further data you may need to thrive in the primary biliary cholangitis therapeutics industry. This primary biliary cholangitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abhilash Pyata

Primary Biliary Cholangitis Therapeutics Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.01 billion
Revenue Forecast In 2034	$1.64 billion
Growth Rate	CAGR of 12.9% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Drug, Mechanism Of Action (MOA), Distribution Channel, Use, Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Primary Biliary Cholangitis Therapeutics Market Characteristics

3. Primary Biliary Cholangitis Therapeutics Market Trends And Strategies

4. Primary Biliary Cholangitis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Biliary Cholangitis Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Primary Biliary Cholangitis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Primary Biliary Cholangitis Therapeutics Market Growth Rate Analysis

5.4. Global Primary Biliary Cholangitis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Primary Biliary Cholangitis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Primary Biliary Cholangitis Therapeutics Total Addressable Market (TAM)

6. Primary Biliary Cholangitis Therapeutics Market Segmentation

6.1. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ursodeoxycholic Acid

Obeticholic Acid

Other Drugs

6.2. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Receptor Agonist

Receptor Modulator

Enzyme Activator

Enzyme Inhibitor

Other Mechanisms Of Action

6.3. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Drug Store And Retail Pharmacies

Online Pharmacies

6.4. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Human

Veterinary

6.5. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Ursodeoxycholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Branded Ursodeoxycholic Acid

Generic Ursodeoxycholic Acid

Combination Therapies With Ursodeoxycholic Acid

6.6. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy

Combination Therapy

Branded Obeticholic Acid

6.7. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Other Drugs, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fibrates

Budesonide

Immunosuppressants

Investigational Drugs Or Pipeline Candidates

7. Primary Biliary Cholangitis Therapeutics Market Regional And Country Analysis

7.1. Global Primary Biliary Cholangitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Primary Biliary Cholangitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market

8.1. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Biliary Cholangitis Therapeutics Market

9.1. China Primary Biliary Cholangitis Therapeutics Market Overview

9.2. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Biliary Cholangitis Therapeutics Market

10.1. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Biliary Cholangitis Therapeutics Market

11.1. Japan Primary Biliary Cholangitis Therapeutics Market Overview

11.2. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Biliary Cholangitis Therapeutics Market

12.1. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Biliary Cholangitis Therapeutics Market

13.1. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Biliary Cholangitis Therapeutics Market

14.1. South Korea Primary Biliary Cholangitis Therapeutics Market Overview

14.2. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Biliary Cholangitis Therapeutics Market

15.1. Western Europe Primary Biliary Cholangitis Therapeutics Market Overview

15.2. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Biliary Cholangitis Therapeutics Market

16.1. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Biliary Cholangitis Therapeutics Market

17.1. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Biliary Cholangitis Therapeutics Market

18.1. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Biliary Cholangitis Therapeutics Market

19.1. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Biliary Cholangitis Therapeutics Market

20.1. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Therapeutics Market

21.1. Eastern Europe Primary Biliary Cholangitis Therapeutics Market Overview

21.2. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Biliary Cholangitis Therapeutics Market

22.1. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Biliary Cholangitis Therapeutics Market

23.1. North America Primary Biliary Cholangitis Therapeutics Market Overview

23.2. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Biliary Cholangitis Therapeutics Market

24.1. USA Primary Biliary Cholangitis Therapeutics Market Overview

24.2. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Biliary Cholangitis Therapeutics Market

25.1. Canada Primary Biliary Cholangitis Therapeutics Market Overview

25.2. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Biliary Cholangitis Therapeutics Market

26.1. South America Primary Biliary Cholangitis Therapeutics Market Overview

26.2. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Biliary Cholangitis Therapeutics Market

27.1. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Biliary Cholangitis Therapeutics Market

28.1. Middle East Primary Biliary Cholangitis Therapeutics Market Overview

28.2. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Biliary Cholangitis Therapeutics Market

29.1. Africa Primary Biliary Cholangitis Therapeutics Market Overview

29.2. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape And Company Profiles

30.1. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape

30.2. Primary Biliary Cholangitis Therapeutics Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Parvus Therapeutics Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Primary Biliary Cholangitis Therapeutics Market Other Major And Innovative Companies

31.1. Ipsen Pharma

31.2. Hanmi Pharmaceutical Co. Ltd.

31.3. Intercept Pharmaceuticals

31.4. Enanta Pharmaceuticals

31.5. Mirum Pharmaceuticals

31.6. Calliditas Therapeutics AB

31.7. Dr. Falk Pharma GmbH

31.8. NGM Biopharmaceuticals Inc.

31.9. Durect Corporation

31.10. COUR Pharmaceuticals

31.11. HighTide Therapeutics Inc.

31.12. Pliant Therapeutics Inc.

31.13. Tiziana Life Sciences

31.14. Phenex Pharmaceuticals

31.15. Synlogic Therapeutics

32. Global Primary Biliary Cholangitis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Therapeutics Market

34. Recent Developments In The Primary Biliary Cholangitis Therapeutics Market

35. Primary Biliary Cholangitis Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Primary Biliary Cholangitis Therapeutics Market In 2029 - Countries Offering Most New Opportunities

35.2 Primary Biliary Cholangitis Therapeutics Market In 2029 - Segments Offering Most New Opportunities

35.3 Primary Biliary Cholangitis Therapeutics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Ursodeoxycholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Other Drugs, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Primary Biliary Cholangitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Primary Biliary Cholangitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: F. Hoffmann-La Roche Ltd Financial Performance

Table 79: Parvus Therapeutics Financial Performance

Table 80: Novartis AG Financial Performance

Table 81: Gilead Sciences Inc. Financial Performance

Table 82: Viatris Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Ursodeoxycholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Other Drugs, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Primary Biliary Cholangitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Primary Biliary Cholangitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: F. Hoffmann-La Roche Ltd Financial Performance

Figure 79: Parvus Therapeutics Financial Performance

Figure 80: Novartis AG Financial Performance

Figure 81: Gilead Sciences Inc. Financial Performance

Figure 82: Viatris Inc. Financial Performance

Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Liver Diseases Therapeutics Global Market Report 2025 – By Disease Type( Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer ), By Treatment( Antiviral, Vaccines, Chemotherapy, Immunosuppressive A...

Cholinergic Drugs Global Market Report 2025 – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myasthenia Gra...

Bipolar Disorder Therapeutics Global Market Report 2025 – By Drug Class (Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs), By Mechanism (Selective Serotonin Reuptake Inhibitors, Serotonin-norepin...

Bronchitis Treatment Global Market Report 2025 – By Type (Acute Bronchitis, Chronic Bronchitis), By Treatment (Drugs, Oxygen Therapy), By Distribution Channel (Online Pharmaceutical Stores, Retail Pharmacies, Hospital Ph...

Lupus Therapeutics Global Market Report 2025 – By Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus), By Treatment Type (Non-Steroidal Anti-...

Liver Health Supplements Global Market Report 2025 – By Product (Vitamin And Minerals, Herbal Supplements, Other Products), By Nature (Organic, Conventional), By Form (Dry, Tablets, Powder, Liquid), By Distribution Chann...

Rheumatology Therapeutics Global Market Report 2025 – By Drug Class (Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes), By Distribution C...

Frequently Asked Questions

What is the definition of the Primary Biliary Cholangitis Therapeutics market?

How will the Primary Biliary Cholangitis Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Primary Biliary Cholangitis Therapeutics industry going forward?

The Primary Biliary Cholangitis Therapeutics market major growth driver - Increasing Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Rising Alcohol Consumption And Liver Damage. For further insights on the Primary Biliary Cholangitis Therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the Primary Biliary Cholangitis Therapeutics market?

The Primary Biliary Cholangitis Therapeutics market size has grown strongly in recent years. The primary biliary cholangitis therapeutics market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising awareness of autoimmune liver diseases, increasing clinical evidence supporting growth in liver function testing, increasing investment in hepatology research, and rising prevalence of autoimmune diseases. The primary biliary cholangitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing adoption of second-line therapies, a growing pipeline of novel therapeutics, a rise in combination therapies, increasing global access to diagnostics and specialty care, and growth in patient advocacy and education initiatives. Major trends in the forecast period include personalized treatment approaches, expansion of second-line therapies, focus on non-invasive biomarkers, emphasis on symptom management, and integration of real-world evidence (RWE). For further insights on the Primary Biliary Cholangitis Therapeutics market, request a sample here

How is the Primary Biliary Cholangitis Therapeutics market segmented?

The primary biliary cholangitis therapeutics market covered in this report is segmented –
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates For further insights on the Primary Biliary Cholangitis Therapeutics market, request a sample here

Which region has the largest share of the Primary Biliary Cholangitis Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the primary biliary cholangitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Primary Biliary Cholangitis Therapeutics market, request a sample here.

Who are the major players in the Primary Biliary Cholangitis Therapeutics market?

What are the key trends in the Primary Biliary Cholangitis Therapeutics market?

Major trends in the Primary Biliary Cholangitis Therapeutics market include Breakthrough In PBC Treatment With Selective Pparδ Activation. For further insights on the Primary Biliary Cholangitis Therapeutics market, request a sample here.